New dilemmas in small-cell lung cancer TNM clinical staging

作者：Zarogoulidis Konstantinos; Latsios Dimitrios; Porpodis Konstantinos; Zarogoulidis Paul^*; Darwiche Kaid; Antoniou Nick; Hohenforst Schmidt Wolfgang; Eleftheriadou Ellada; Boutsikou Efimia; Kontakiotis Theodoros

来源：OncoTargets and Therapy, 2013, 6: 539-547.

DOI：10.2147/OTT.S44201

• small-cell lung cancer
• staging
• lung cancer

Background: Many patients with limited disease (LD) behave similarly to those with extensive disease (ED) from a prognostic point of view. On the other hand, a proportion of patients with ED small-cell lung cancer (SCLC) behave similarly to those with LD. %26lt;br%26gt;Patients and methods: In this retrospective study analysis, 764 patients with proven SCLC were included and managed with the same therapeutic protocols. Of these patients, 278 (36.4%) had LD, while 486 (63.6%) had ED. %26lt;br%26gt;Results: No statistically significant difference was observed for survival for IA and IB disease stages (P = 0.254) and between IIA and IIB stages (P = 0.256) according to the new tumor, node, metastasis (TNM) staging classification classification. In addition, no statistical significant difference was observed for survival between patients with (IIA + IIB) and IIIA (P = 0.951), (IIA + IIIA, P = 0.658), and (IIB + IIIA, P = 0.573) stages. Statistical significant difference was observed for survival among the LD SCLC patients with (IA + IB), (IIA + IIB + IIIA), and IIIB stages (P %26lt; 0.001). Similarly, statistical significance was observed for ED SCLC patients with (IIA + IIB + IIIA), IIIB, and IV stages (P %26lt; 0.001). %26lt;br%26gt;Conclusions: Although stratification of SCLC patients in LD and ED is generally satisfactory, the TNM staging system is recommended for more detailed prognostic information and treatment evaluation in these patients.

• 出版日期2013